HCPCS G2082: Outpatient Visit with Esketamine Nasal Self-Administration - OpenPayer

Summary & Overview

HCPCS G2082: Outpatient Visit with Esketamine Nasal Self-Administration

HCPCS Level II code G2082 identifies an outpatient evaluation-and-management visit for an established patient that includes supervision and provision of up to 56 mg of esketamine nasal self-administration plus a mandated two-hour post-administration observation. This code matters nationally as esketamine has unique administration and monitoring requirements that affect outpatient workflows, staffing, and payment classification for behavioral health and outpatient infusion/medication programs.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage patterns and common modifiers used with the code where available, plus clinical and operational context for facilities implementing esketamine self-administration visits.

Readers will learn the clinical scope of the code, typical site-of-service implications, and the types of benchmarks and policy updates that influence billing and utilization for esketamine outpatient administration. The piece also flags where input data are unavailable and where organizations should seek payer-specific guidance for coverage and claims submission.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG2082HCPCS Level IIesketamineoutpatient visitE/M supervisionmedication administrationbehavioral healthobservation servicesnasal spray

Billing Code Overview

HCPCS Level II code G2082 describes an office or other outpatient visit for the evaluation and management of an established patient that requires physician or qualified health care professional supervision and includes provision of up to 56 mg of esketamine nasal self-administration with 2 hours post-administration observation.

Service type: Medication administration and E/M supervision for esketamine self-administration.

Typical site of service: Office or other outpatient setting where clinicians can supervise administration and provide the required observation period.

Data not available in the input.

Clinical & Coding Specifications

Clinical Context

A 42-year-old established patient with treatment-resistant major depressive disorder presents to an outpatient behavioral health clinic for supervised esketamine nasal self-administration. The patient has met prior authorization criteria, has a recent baseline assessment by the supervising physician, and arrives with an escort for post-administration monitoring. The clinic staff confirms informed consent, reviews vital signs, assesses recent medication changes and substance use, and completes pre-dose screening for blood pressure and suicidality. The patient self-administers up to 56 mg esketamine nasal spray under direct supervision of a registered nurse and a physician or other qualified health care professional on site. The clinic documents start and stop times for administration, provides a safe reclined area, and conducts continuous observation for 2 hours post-administration for blood pressure monitoring and adverse effects. At the end of observation, the supervising clinician documents clinical stability, provides discharge instructions including the requirement for an escort to drive, and schedules the next treatment visit. Typical site of service is an office or other outpatient clinic designated for supervised intranasal esketamine administration equipped for observation and emergency response.

Coding Specifications

Modifier	Description	When to Use
`11`

HCPCS G0163: Skilled Nursing Observation and Assessment, Home Health/Hospice

HCPCS-G9537-IMAGING-CLINICAL-TRIAL-OR-EXTERNAL-ORDER

HCPCS G9537: Imaging for Clinical Trial or Externally Ordered Study

HCPCS-G8706-DOCUMENTATION-NO-12-LEAD-ECG

HCPCS G8706: Documentation of Reason for Not Performing 12-Lead ECG

HCPCS-G4037-UROLOGY-MIPS-SPECIALTY-SET

HCPCS G4037: Urology MIPS Specialty Set

HCPCS-G9004-COORDINATED-CARE-FEE-INITIAL-LOW-RISK

HCPCS G9004: Coordinated Care Fee, Risk-Adjusted Low, Initial

HCPCS-G0557-ADVANCED-PRIMARY-CARE-MANAGEMENT

HCPCS G0557: Advanced Primary Care Management for Complex Chronic Patients

HCPCS-G8570-PROLONGED-POSTOPERATIVE-INTUBATION-NOT-REQUIRED

HCPCS G8570: Prolonged Postoperative Intubation Not Required

HCPCS-G8883-BIOPSY-RESULTS-REVIEW-COMMUNICATION-TRACKING

HCPCS G8883: Biopsy Results Review, Communication, and Tracking

HCPCS-G9724-ANTICOAGULANT-MEDICATION-USE-DOCUMENTATION

HCPCS G9724: Anticoagulant Medication Use Documented Over Measurement Year

HCPCS-G8947-NEUROPSYCHIATRIC-SYMPTOM-ASSESSMENT

HCPCS G8947: One or More Neuropsychiatric Symptoms

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
`207Q00000X`	Psychiatry & Neurology	Psychiatrists typically supervise esketamine treatment and oversee dosing and monitoring.
`363L00000X`	Nurse Practitioner	Psychiatric nurse practitioners frequently manage medication administration and monitoring under collaborative practice.
`177T00000X`	Physician Assistant	Physician assistants in behavioral health clinics may supervise administration and perform assessments.
`208000000X`	Family Medicine	Family physicians in integrated clinics may provide and supervise outpatient esketamine dosing.
`334W00000X`	Nursing — Registered Nurse	Registered nurses provide direct supervision, monitoring, and documentation during administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F33.1`	Major depressive disorder, recurrent, moderate	Common diagnosis for which esketamine is indicated when treatment-resistant.
`F33.2`	Major depressive disorder, recurrent severe without psychotic features	Severe recurrent depression is a typical indication for supervised esketamine therapy.
`F32.9`	Major depressive disorder, single episode, unspecified	May be used when episode detail is unspecified but patient qualifies for esketamine based on severity and treatment resistance.
`F33.0`	Major depressive disorder, recurrent, mild	Less common but can be present in treatment-resistant cases requiring advanced therapy.
`F33.42`	Major depressive disorder, recurrent, in remission	Used for ongoing maintenance visits if clinically indicated and documented.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`99213`	Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutes	May be used for the pre-treatment evaluation or routine follow-up visit on a day without dosing or for brief medication management discussions.
`99214`	Office or other outpatient visit for the evaluation and management of an established patient, typically 25 minutes	Used for more complex pre-dose assessments or extended monitoring discussions when medical decision-making is moderate in complexity.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance)	Not directly used for intranasal administration but may be reported when injectable medications are administered during the same encounter.
`99406`	Smoking and tobacco use cessation counseling visit, intermediate, greater than 3 minutes up to 10 minutes	Supportive counseling services sometimes provided during behavioral health visits related to overall treatment planning.
`99499`	Unlisted evaluation and management service	Used only when an encounter’s services do not fit standard E/M codes and additional documentation supports nonstandard billing.

OpenPayer